Harvard Bioscience Inc(HBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 18 at 7:30 PM ET (Korea 9/19 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.32 | Insider Own | 7.15% | Shs Outstand | 4.5M | Perf Week | -1% |
| Market Cap | 0.04B | Forward P/E | 12.33 | EPS next Y | 269.74% | Insider Trans | 12.44% | Shs Float | 4.2M | Perf Month | 12.29% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | -0.17 | Inst Own | 44.37% | Short Float | 1.15% | Perf Quarter | 35.43% |
| Income | -0.01B | P/S | 0.41 | EPS this Y | -90% | Inst Trans | 3.19% | Short Ratio | 2.87 | Perf Half Y | 41.96% |
| Sales | 0.09B | P/B | 4.88 | EPS next 5Y | - | ROA | -13.32% | Short Interest | 0.05M | Perf YTD | 18.87% |
| Book/sh | 1.63 | P/C | 5.57 | EPS past 3/5Y | -77.14% -44.59% | ROE | -89.95% | 52W High | -15.43% ($9.40) | Perf Year | 64.49% |
| Cash/sh | 1.43 | P/FCF | - | Sales past 3/5Y | -8.6% -3.25% | ROIC | -20.81% | 52W Low | 111.72% ($3.76) | Perf 3Y | -81.68% |
| Dividend Est. | - | EV/EBITDA | 12.38 | EPS Y/Y TTM | 82.17% | Gross Margin | 54.35% | Volatility(W/M) | 2.14% 3.48% | Perf 5Y | -89.62% |
| Dividend TTM | - | EV/Sales | 0.84 | Sales Y/Y TTM | -1.06% | Oper. Margin | 0.65% | ATR (14) | 0.26 | Perf 10Y | -69.54% |
| Dividend Ex-Date | - | Quick Ratio | 0.98 | EPS Q/Q | -24.83% | Profit Margin | -11.86% | RSI (14) | 61.22 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.87 | Sales Q/Q | 11.13% | SMA20 | 0.26% ($7.93) | Beta | 1.51 | Target Price | $7.5 |
| Payout | - | Debt/Eq | 5.96 | Earnings | 2026/8/11 | SMA50 | 14.41% ($6.95) | Rel Volume | 1.14 | Prev Close | $8.03 |
| Employees | 339 | LT Debt/Eq | 5.74 | EPS/Sales Surpr. | 33.33% 5.95% | SMA200 | 27.2% ($6.25) | Avg Volume(3M) | 0.02M | Price | $7.95 |
| IPO | 2000/12/7 | Option/Short | No/Yes | Trades | 345 | Volume | 19,221 | Change | -1% |
Company
HBIO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🔬 This is a US small- to mid-cap life sciences tools company that manufactures and sells precision laboratory instruments and consumables used across a wide range of life science research applications, including electrophysiology, cell analysis, animal telemetry, electroporation, and laboratory fluid handling.
Over the past 1 year, roughly in the middle
15% below its 1-year high.
HBIO has weak earning power
0.65% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -90.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -81.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 44.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
DFAC 0.00%
DFAS 0.00%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $36M.
HBIO $36M PER -
ISRG $139B PER 45.1
BDX $49B PER 54.6
MDLN $42B PER 37.1
FAQ
What kind of company is HBIO?
HBIO belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of HBIO?
The market cap of HBIO is approximately $36M, ranking 5,085 within its sector.
What is the 52-week high and low for HBIO?
HBIO has recorded a 52-week high of $9.40 and a low of $3.76.
